Pfizer (PFE) Stock Price, News & Analysis

Company Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Key Stats

• Today's Range: $23.94 to $24.47
• 50-Day Range: $23.11 to $25.77
• 52-Week Range: $20.92 to $30.43
• Volume: 45.47 million shs
• Average Volume: 46.19 million shs
• Market Capitalization: $137.84 billion
• P/E Ratio: 12.90
• Dividend Yield: 7.09%
• Price Target: $28.44
• Consensus Rating: Moderate Buy

Pfizer Stock Analysis - MarketRank™

Pfizer scored higher than 100% of companies evaluated by MarketBeat, and ranked 8th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Pfizer has received a consensus rating of Hold. The company's average rating score is 2.39, and is based on 4 buy ratings, 11 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Pfizer has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 2.71%

Earnings Growth

Earnings for Pfizer are expected to grow by 2.71% in the coming year, from $2.95 to $3.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pfizer is 12.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.24.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pfizer is 12.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.84.

Price to Earnings Growth Ratio

Pfizer has a PEG Ratio of 0.87. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Pfizer has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.75% of the outstanding shares of Pfizer have been sold short.

Short Interest Ratio / Days to Cover

Pfizer has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pfizer has recently decreased by 11.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Leadership

Pfizer is a leading dividend payer. It pays a dividend yield of 7.19%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Pfizer has been increasing its dividend for 16 years.

Dividend Coverage

The dividend payout ratio of Pfizer is 124.64%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Pfizer will have a dividend payout ratio of 56.77% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -2.19

Percentage of Shares Shorted

1.75% of the outstanding shares of Pfizer have been sold short.

Short Interest Ratio / Days to Cover

Pfizer has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pfizer has recently decreased by 11.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.80

News Sentiment

Pfizer has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 164 news articles for Pfizer this week, compared to 70 articles on an average week.

Search Interest

277 people have searched for PFE on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.

MarketBeat Follows

68 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 55% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pfizer insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.06% of the stock of Pfizer is held by insiders.

Percentage Held by Institutions

68.36% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PFE Stock Analysis - Frequently Asked Questions

How have PFE shares performed this year?

Pfizer's stock was trading at $26.53 at the beginning of the year. Since then, PFE shares have decreased by 8.6% and is now trading at $24.2450.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) issued its quarterly earnings results on Tuesday, August, 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer's quarterly revenue was up 10.3% compared to the same quarter last year.
Read the conference call transcript.

Does Pfizer have any subsidiaries?

Pfizer subsidiaries include ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and more.

Who are Pfizer's major shareholders?

Top institutional shareholders of Pfizer include Bank of New York Mellon Corp (0.63%), Sumitomo Mitsui Trust Group Inc. (0.27%), Envestnet Asset Management Inc. (0.20%) and Mitsubishi UFJ Asset Management Co. Ltd. (0.19%). Insiders that own company stock include Pfizer Inc, Ronald E Blaylock and Scott Gottlieb.
View institutional ownership trends.

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include Scilex (SCLX), Salesforce (CRM), Chevron (CVX), AbbVie (ABBV), Johnson & Johnson (JNJ), Meta Platforms (META) and Bristol Myers Squibb (BMY).

Company Calendar

• Record date for 6/13 Dividend: 5/09/2025
• Ex-Dividend for 6/13 Dividend: 5/09/2025
• Dividend Payable: 6/13/2025
• Record date for 9/2 Dividend: 7/25/2025
• Ex-Dividend for 9/2 Dividend: 7/25/2025
• Last Earnings: 8/05/2025
• Today: 8/07/2025
• Dividend Payable: 9/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:PFE
• CIK: 78003
• Web: www.pfizer.com
• Phone: (212) 733-2323
• Fax: 302-655-5049
• Employees: 81,000
• Year Founded: 1849

Price Target and Rating

• Average Price Target for Pfizer: $28.12
• High Price Target: $33.00
• Low Price Target: $23.00
• Potential Upside/Downside: +16.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.39
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.38
• Trailing P/E Ratio: 12.90
• Forward P/E Ratio: 8.22
• P/E Growth: 0.87
• Net Income: $8.03 billion
• Net Margins: 16.84%
• Pretax Margin: 16.50%
• Return on Equity: 21.42%
• Return on Assets: 9.12%

Debt

• Debt-to-Equity Ratio: 0.65
• Current Ratio: 1.16
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $63.63 billion
• Price / Sales: 2.17
• Cash Flow: $4.42 per share
• Price / Cash Flow: 5.48
• Book Value: $15.66 per share
• Price / Book: 1.55

Miscellaneous

• Outstanding Shares: 5,685,550,000
• Free Float: 5,681,955,000
• Market Cap: $137.85 billion
• Optionable: Optionable
• Beta: 0.52